Category: 38939-88-7

On October 29, 1992, Shibayama, Katsuhiro; Makino, Tetsuya; Imaoka, Takayuki; Katou, Tetsuya; Kaneko, Masayuki published a patent.Formula: C7H6ClNO2 The title of the patent was Preparation of tricyclic triazole derivatives as antiinflammatory, antiallergic, and anti-platelet activating factor (PAF) drugs. And the patent contained the following:

The title compounds [I; R1 = H, alkyl, C3-5 cycloalkyl; R2, R3 = H, alkyl, alkoxy, halo; W = CO, CR4R5; R4, R5 = H, alkyl; A = C1-5 linear or branched (un)saturated alkylene optionally containing heteroatoms; l = 0-2; n = 1-3; Y = N, C; Z = C(B)Ar1Ar2, CAr1Ar2, OCHAr1Ar2, fused aromatic ring; B = H, HO, MeO; Ar1, Ar2 = H, (un)substituted aryl] are prepared Thus, cyclocondensation of 4-(3-ethoxypropyl)-2-chloroquinoxaline (preparation given) with acetohydrazide in BuOH under reflux and bromination of the the resulting [1,2,4]triazolo[4,3-a]quinoxaline derivative (II; R6 = OEt) with 48% HBr followed by condensation with 4-(diphenylmethylene)piperidine and NaCO3 in DMF at 60-70° gave a title compound (II; R6 = Q). I at 50 mg/kg p.o. inhibited 44-75% passive cutaneous anaphylaxis and 19-87% histamine-induced allergy in rats. I showed IC50 of 0.013-5.4 μg/mL for inhibiting PAF-induced rabbit’s blood platelet aggregation. A tablet formulation containing II (R6 = Q1) was given. A total of 121 I were prepared The experimental process involved the reaction of 2-Chloro-4-methyl-1-nitrobenzene(cas: 38939-88-7).Formula: C7H6ClNO2

The Article related to tricyclic triazole preparation antiinflammatory, antiallergic triazoloquinoxaline triazolobenzodiazepine, platelet activating factor antagonist triazoloquinoxaline, paf antagonist triazoloquinoxaline, blood platelet aggregation inhibitor triazoloquinoxaline, triazolobenzimidazole antiinflammatory and other aspects.Formula: C7H6ClNO2

Referemce:
Chloride – Wikipedia,
Chlorides – an overview | ScienceDirect Topics

On March 25, 2010, Kajino, Masahiro; Imaeda, Toshihiro; Ono, Koji; Aso, Kazuyoshi; Tarui, Naoki published a patent.Synthetic Route of 38939-88-7 The title of the patent was Preparation of 2-aminobenzimidazole derivatives as gastric acid secretion inhibitors. And the patent contained the following:

There are disclosed acid secretion inhibitors containing compounds represented by formula [I; R1’s may be the same or different and each represents a hydrogen atom, a halogen atom, an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group, an optionally substituted alkoxy group, a hydroxy group or an optionally substituted amino group; R2 represents a hydrogen atom or a substituent; R3 represents a hydrogen atom or a substituent; ring A represents an optionally substituted carbon ring or an optionally substituted heterocyclic ring; and n represents an integer of 1-4], salts thereof, or prodrugs of the compounds or salts. These compounds inhibit proton,potassium-ATPase (H+/K+-ATPase) and are useful as gastric acid secretion inhibitors. There is also provided the preventive or therapeutic method for peptic ulcer, Zollinger-Ellison syndrome, gastritis, gastroesophageal reflux disease (GERD), symptomatic gastroesophageal reflux disease (symptomatic GERD), Barrett esophagus, functional dyspepsia, gastric cancer (stomach cancer), gastric MALT lymphoma, ulcer caused by nonsteroidal antiinflammatory agents, ulcer or hyper-gastric acidity (excessive acid secretion) caused by postsurgical stress, acute stress ulcer, hemorrhagic gastritis, stress, or upper digestive tract hemorrhage by administering the compound in mammals. Thus, a solution of 666 mg benzene-1,2-diamine in 30 mL THF was treated with 1.08 g 2-isothiocyanato-1,3,5-trimethyl benzene, refluxed for 4 h, treated with 2.24 g 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride, and refluxed for 50 min to give, after workup and recrystallization from EtOAc/hexane, 253 mg N-(2,4,6-trimethylphenyl)-1H-benzimidazol-2-amine (II). II N-(4-fluoro-2,6-dimethylphenyl)-5-methoxy-4-methyl-1H-benzimidazol-2-amine (III) showed IC50 of 970 and 14 nM, resp., against H+/K+-ATPase. A tablet formulation containing I was described. The experimental process involved the reaction of 2-Chloro-4-methyl-1-nitrobenzene(cas: 38939-88-7).Synthetic Route of 38939-88-7

The Article related to aminobenzimidazole preparation gastric acid secretion inhibitor, proton potassium atpase inhibitor aminobenzimidazole preparation, peptic ulcer zollinger ellison syndrome prevention treatment aminobenzimidazole preparation, gastritis gastroesophageal reflux disease gerd prevention treatment aminobenzimidazole preparation and other aspects.Synthetic Route of 38939-88-7

Referemce:
Chloride – Wikipedia,
Chlorides – an overview | ScienceDirect Topics

On September 29, 1993, Axelsson, Oskar; Peters, Dan; Nielsen, Elsebet Ostergaard; Christophersen, Palle published a patent.Electric Literature of 38939-88-7 The title of the patent was Imidazole compounds, their preparation and use. And the patent contained the following:

The title compounds, particularly the benzimidazole derivatives and 3H-imidazo[4,5-b]pyridine derivatives, I (X, Y = carbon, nitrogen; R12, R13 = alkyl; R4-R7 = H, halo, amino, cyano, etc.) and their uses for the treatment of diseases responsive to blocking of calcium channels of the central nervous system are claimed. Such diseases include degenerative changes associated with stroke, ischemia, migraine, psychosis, Parkinson’s disease, depression, epilepsy, or convulsive disorders. For example, 1-(4-iodophenyl)-4-fluorobenzimidazole (II) had an in vitro activity as L-type calcium channel blocker. Other I were tested for activity as N-type and P-type calcium channel blockers. The experimental process involved the reaction of 2-Chloro-4-methyl-1-nitrobenzene(cas: 38939-88-7).Electric Literature of 38939-88-7

The Article related to ischemia benzimidazole imidaopyridine phenyl, migraine benzimidazole imidaopyridine phenyl, antipsychotic benzimidazole imidaopyridine phenyl, antidepressant benzimidazole imidaopyridine phenyl, antiepileptic benzimidazole imidaopyridine phenyl, anticonvulsant benzimidazole imidaopyridine phenyl, calcium channel blocker benzimidazole imidaopyridine and other aspects.Electric Literature of 38939-88-7

Referemce:
Chloride – Wikipedia,
Chlorides – an overview | ScienceDirect Topics